IGSF8
Sign in to saveAlso known as CD316, CD81P3, EWI-2, EWI2, KCT-4, LIR-D1, PGRL, immunoglobulin superfamily member 8
Immunoglobulin superfamily member 8 is a protein that in humans is encoded by the IGSF8 gene. IGSF8 has also been designated as CD316 (cluster of differentiation 316). IGSF8 is an innate immune checkpoint that inhibits the cytotoxic activity of natural killer (NK) cells. IGSF8 acts by binding to the Killer Ig-like Receptor KIR3DL2 (or, in mice, the analogous Klra9 receptor). IGSF8 is frequently overexpressed relative to normal tissues in many cancers, included melanoma, urothelial carcinoma, and breast cancer, and has been proposed as a potential therapeutic target in gliomas. In normal tissue
Gene data
IGSF8- Name
- immunoglobulin superfamily member 8
- Type
- protein-coding
- Aliases
- CD316, CD81P3, EWI-2, EWI2, KCT-4, LIR-D1, PGRL
This gene encodes a member the EWI subfamily of the immunoglobulin protein superfamily. Members of this family contain a single transmembrane domain, an EWI (Glu-Trp-Ile)-motif and a variable number of immunoglobulin domains. This protein interacts with the tetraspanins CD81 and CD9 and may regulate their role in certain cellular functions including cell migration and viral infection. The encoded protein may also function as a tumor suppressor by inhibiting the proliferation of certain cancers. Alternate splicing results in multiple transcript variants that encode the same protein. [provided by RefSeq, Sep 2011].
via MyGene.info
Wikidata facts
Show 5 more facts
- HomoloGene ID
- 14163
- exact match
- identifiers.org/ncbigene/93185
- genomic end
- 160068733
- genomic start
- 160061130
- cytogenetic location
- 1q23.2
Sources (3)
via Wikidata · CC0
~1 min read
Article
4 sectionsContents
- Cancer biomarker
- References
- Further reading
- External links
Immunoglobulin superfamily member 8 is a protein that in humans is encoded by the IGSF8 gene. IGSF8 has also been designated as CD316 (cluster of differentiation 316). IGSF8 is an innate immune checkpoint that inhibits the cytotoxic activity of natural killer (NK) cells. IGSF8 acts by binding to the Killer Ig-like Receptor KIR3DL2 (or, in mice, the analogous Klra9 receptor). IGSF8 is frequently overexpressed relative to normal tissues in many cancers, included melanoma, urothelial carcinoma, and breast cancer, and has been proposed as a potential therapeutic target in gliomas. In normal tissues, IGSF8 is highly expressed in the brain, where it may contribute to the immune privilege of the central nervous system.
== Cancer biomarker == In gliomas, IGSF8 is strongly correlated with tumor grade and is a potential prognostic marker. IGSF8 is enriched on ovarian cancer-derived extracellular vesicles and is a potential biomarker for the early detection of high grade serous ovarian cancer.